A Part of the University of Maryland Medical Center

Connect with UMGCC
Facebook Twitter YouTube Blog iPhone
Email PageEmail page Print PagePrint page

ASH Annual Meeting – Dec 8-11, 2012

University of Maryland Greenebaum Cancer Center Presentations

Maintenance Therapy with Decitabine in Younger Adults with Acute Myeloid Leukemia (AML) in First Remission: A Phase II Cancer and Leukemia Group B Study (CALGB 10503, Alliance)

William Blum, MD1, Ben Sanford2*, Rebecca B Klisovic, MD1, Daniel J. DeAngelo, MD, PhD3*, Geoffrey Uy, MD4, Bayard L. Powell, MD5, Wendy Stock, MD5, Maria R. Baer, M.D.7, Jonathan E. Kolitz, MD8, Meir Wetzler, MD9, Eva Hoke2*, Clara D. Bloomfield, MD10*, Susan Geyer, PhD11,12*, Guido Marcucci, MD13,14, Richard M. Stone, MD15 and Richard A. Larson, MD16

Number: 44
Program: Oral and Poster Abstracts
Session: 615. Acute Myeloid Leukemia - Therapy, excluding Transplantation: Novel Therapies
Time and Location:
Sunday, December 9, 2012: 12:00 PM-1:30 PM
A101 (Georgia World Congress Center)

The Pim Kinase Inhibitor SGI-1776 Chemosensitizes Multidrug Resistant Cells by Both Inhibiting Drug Transport by ABCB1 and ABCG2 and Decreasing ABCB1 and ABCG2 Surface Expression On Cells That Overexpress Pim-1

Karthika Natarajan, PhD1*, Jasjeet Bhullar, PhD1*, Suneet Shukla, PhD2*, Mehmet Burcu, BS1*, Suresh V. Ambudkar, PhD2* and Maria R. Baer, M.D.1

Number: 2462
Program: Oral and Poster Abstracts
Session: 604. Molecular Pharmacology, Drug Resistance: Poster II
Time and Location:
Sunday, December 9, 2012: 6:00 PM-8:00 PM
Hall B1-B2 (Georgia World Congress Center)

Glutaminase Inhibition Selectively Slows the Growth of Primary Acute Myeloid Leukemia (AML) Cells with Isocitrate Dehydrogenase (IDH) Mutations

Ashkan Emadi, M.D., Ph.D.1, Sung Ah Jun, BSc2*, Takashi Tsukamoto, Ph.D.3*, Amir T Fathi, MD4, Mark D. Minden, MD, PhD5 and Chi Van Dang, M.D., Ph.D.6*

Number: 2624
Program: Oral and Poster Abstracts
Session: 615. Acute Myeloid Leukemia - Therapy, excluding Transplantation: Poster II
Time and Location:
Sunday, December 9, 2012: 6:00 PM-8:00 PM
Hall B1-B2 (Georgia World Congress Center)

Short Survival and High Rates of Transformation Prevail in Chronic Myelomonocytic Leukemia Despite Hypomethylating Agent Therapy

Emily J. Vannorsdall, M.D.1*, Vu H. Duong, M.D.2, Xinyi Ng, B.S.3*, Dan P. Zandberg, M.D.2*, Michael L. Tidwell, C.R.N.P.1*, Amy J. Davidoff, M.S., Ph.D.3* and Maria R. Baer, M.D.2

Number: 2800
Program: Oral and Poster Abstracts
Session: 633. Myelodysplastic Syndromes: Poster II
Time and Location:
Sunday, December 9, 2012: 6:00 PM-8:00 PM
Hall B1-B2 (Georgia World Congress Center)

A Pilot Study of Acupuncture in Treating Bortezomib-Induced Peripheral Neuropathy (BIPN) in Multiple Myeloma (MM) Patients

Ting Bao, MD1,2*, Neil Porter, MD3*, James Primrose, RN1*, Olga Goloubeva1*, Lisa Hester4*, Lulu Wang, MS1*, Mariola Sadowska, PhD5*, Rena Lapidus, PhD5*, Michelle Medeiros, MS, MA1*, Lixing Lao, PhD, L.Ac.2*, Susan Dorsey, RN, PhD5* and Ashraf Z. Badros, MD1

Number: 3168
Program: Oral and Poster Abstracts
Session: 901. Health Services and Outcomes Research: Poster II
Time and Location:
Sunday, December 9, 2012: 6:00 PM-8:00 PM
Hall B1-B2 (Georgia World Congress Center)

Medicare Prescription Drug Coverage and Home Use of Erythropoiesis-Stimulating Agents for MDS-Associated Anemia: A Medicare-Database Analysis

Amy J. Davidoff, M.S., Ph.D.1*, Franklin Hendrick, B.S.1*, Bruce C. Stuart, PhD1*, Amer M. Zeidan, MD2, Rahul Shenolikar, PhD3*, Steven D. Gore, MD2 and Maria R. Baer, M.D.4

Number: 3176
Program: Oral and Poster Abstracts
Session: 901. Health Services and Outcomes Research: Poster II
Time and Location:
Sunday, December 9, 2012: 6:00 PM-8:00 PM
Hall B1-B2 (Georgia World Congress Center)

Utilization Patterns of Iron Chelation Therapy in Transfusion-Dependent Myelodysplastic Syndrome Patients Enrolled in Medicare Part D

Amer M. Zeidan, MD1, Maria R. Baer, M.D.2, Steven D. Gore, MD1, Medha Sasane, BPharm, PhD3*, Carole Paley, MD3*, Diane L. McNally, BSPharm, M.S.4* and Amy J. Davidoff, M.S., Ph.D.5*

Number: 3178
Program: Oral and Poster Abstracts
Session: 901. Health Services and Outcomes Research: Poster II
Time and Location:
Sunday, December 9, 2012: 6:00 PM-8:00 PM
Hall B1-B2 (Georgia World Congress Center)

Combination Immunotherapy After ASCT for Multiple Myeloma (MM) Using MAGE-A3/Poly-ICLC Immunizations Followed by Vaccine-Primed and Activated Autologous T-Cells

Aaron P. Rapoport, MD1, Nicole A. Aqui, MD2*, Edward A. Stadtmauer, MD3, Ashraf Z. Badros, MD4, Dan T. Vogl, MD, MSCE5, YinYan Xu2*, Brendan M Weiss, MD3, Ling Cai, PhD6*, Hong-Bin Fang, PhD7*, Elizabeth Veloso, RN, JD8*, Zhaohui Zheng, MA2*, Saul Yanovich, MD9, Gorgun Akpek, MD, MHS1*, Sunita Philip10*, Kathleen Ruehle, RN9*, Kelly-Marie Betts, MS1*, Anne Chew, PhD11*, Holly McConville, RN, BSN3*, Sandra Westphal1*, Scott Strome12*, Andres Salazar, MD13*, Bruce L. Levine, PhD2* and Carl H. June, MD3

Number: 352
Program: Oral and Poster Abstracts
Session: 723. Clinical Allogeneic and Autologous Transplantation - Late Complications and Approaches to Disease Recurrence: Improving Transplant Outcomes Through Immunomodulation
Time and Location:
Monday, December 10, 2012: 7:00 AM-8:30 AM
C108-C109 (Georgia World Congress Center)

Deferasirox Is Associated with Reduced Mortality Risk in a Medicare Population with Myelodysplastic Syndromes

Amer M. Zeidan, MD1, Franklin Hendrick, B.S.2*, Erika Friedmann, PhD3*, Steven D. Gore, MD1, Maria R. Baer, M.D.4, Medha Sasane, BPharm, PhD5*, Carole Paley, MD5*, Diane L. McNally, BSPharm, M.S.6* and Amy J. Davidoff, M.S., Ph.D.2*

Number: 426
Program: Oral and Poster Abstracts
Session: 633. Myelodysplastic Syndromes: Updates on Therapy and Prognosis
Time and Location:
Monday, December 10, 2012: 10:30 AM-12:00 PM
B216-B217 (Georgia World Congress Center)

Adoptive Transfer of Gene-Modified T-Cells Engineered to Express High-Affinity TCRs for Cancer-Testis Antigens (CTAs) NY-ESO-1 or Lage-1, in MM Patients Post Auto-SCT

Aaron P. Rapoport, MD1, Edward A. Stadtmauer, MD2*, Dan T. Vogl, MD, MSCE3, Brendan M Weiss, MD3, Gwendolyn K. Binder-Scholl, PhD4*, Joanna E. Brewer, PhD5*, Alan D. Bennett, PhD5*, Andrew B. Gerry, PhD5*, Nick J. Pumphrey, PhD5*, Dominic P. Smethurst, MD5*, Helen K. Tayton-Martin, PhD5*, Ribeiro C. Lilliam, MBe4*, Elizabeth Veloso, JD, BSN3*, Zhaohui Zheng, MA6*, Ashraf Z. Badros, MD1, Saul Yanovich, MD1, Gorgun Akpek, MD, MHS1*, Holly McConville, RN, BSN3*, Naseem Kerr, MPH3*, Sunita Philip, MPH1*, Kelly-Marie Betts, MS1*, Sandra Westphal1*, Michael Kalos, PhD3, Bruce L. Levine, PhD6*, Bent K. Jakobsen, PhD5* and Carl H. June, MD2,5

Number: 472
Program: Oral and Poster Abstracts
Session: 731. Clinical Allogeneic and Autologous Transplantation - Results: Strategies to Prevent or Treat Relapse After Transplantation
Time and Location:
Monday, December 10, 2012: 10:30 AM-12:00 PM
B312-B313a (Georgia World Congress Center)

Prolonged T Cell Persistence, Homing to Marrow and Selective Targeting of Antigen Positive Tumor in Multiple Myeloma Patients Following Adoptive Transfer of T Cells Genetically Engineered to Express an Affinity-Enhanced T Cell Receptor Against the Cancer Testis Antigens NY-ESO-1 and Lage-1

Michael Kalos, PhD1,2,3, Aaron P. Rapoport, MD4, Edward A. Stadtmauer, MD2, Dan T. Vogl, MD2, Brendan M Weiss, MD2, Gwendolyn K. Binder-Scholl, PhD5*, Dominic P. Smethurst, MD6*, Irina Kulikovskaya1,3*, Minnal Gupta1,3*, Timothy L Macatee1,3*, Jeffrey M Finklestein1,3*, Joanna E. Brewer, PhD5*, Alan D. Bennett, PhD6*, Andrew B. Gerry, PhD5*, Nick J. Pumphrey, PhD6*, Helen K. Tayton-Martin, PhD6*, Elizabeth Veloso, JD, BSN2*, Zhaohui Zheng, MA7*, Ashraf Z. Badros, MD8, Saul Yanovich, MD8, Gorgun Akpek, MD, MHS8*, Holly McConville, RN, BSN2*, Sunita Philip8*, Bruce L. Levine, PhD9*, Bent K. Jakobsen, PhD5* and Carl H. June, MD7,10

Number: 755
Program: Oral and Poster Abstracts
Session: 801. Gene Therapy and Transfer I
Time and Location:
Monday, December 10, 2012: 4:30 PM-6:00 PM
C208-C210 (Georgia World Congress Center)

Lenalidomide Performance in the Real World: Patterns of Utilization and Effectiveness in a Medicare Population with Myelodysplastic Syndromes

Amer M. Zeidan, MD1, Steven D. Gore, MD1, Diane L. McNally, BSPharm, M.S.2*, Maria R. Baer, M.D.3, Franklin Hendrick, B.S.4*, Dalia Mahmoud, MBA5* and Amy J. Davidoff, M.S., Ph.D.4*

Number: 3837
Program: Oral and Poster Abstracts
Session: 633. Myelodysplastic Syndromes: Poster III
Time and Location:
Monday, December 10, 2012: 6:00 PM-8:00 PM
Hall B1-B2 (Georgia World Congress Center)

Lack of Response of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) to Decitabine After Failure of Azacitidine

Bhavana Bhatnagar, DO1, Dan P. Zandberg, M.D.1*, Emily J. Vannorsdall, M.D.1*, Alison P. Duffy, Pharm.D.1*, Michael L. Tidwell, C.R.N.P.1*, Yi Ning2*, Qing Chen, M.D.1* and Maria R. Baer, M.D.1

Number: 3858
Program: Oral and Poster Abstracts
Session: 633. Myelodysplastic Syndromes: Poster III
Time and Location:
Monday, December 10, 2012: 6:00 PM-8:00 PM
Hall B1-B2 (Georgia World Congress Center)

A Phase 1b Study of 30-Minute Infusion Carfilzomib 20/45 and 20/56 Mg/m2 Plus 40 Mg Weekly Dexamethasone in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma

Ashraf Z. Badros, MD1, Kyriakos P Papadopoulos, MD2, Naseem Zojwalla, MD3*, Ju RueyJiuan Lee, PhD3* and David S. Siegel, MD, PhD4

Number: 4036
Program: Oral and Poster Abstracts
Session: 653. Myeloma - Therapy, excluding Transplantation: Poster III
Time and Location:
Monday, December 10, 2012: 6:00 PM-8:00 PM
Hall B1-B2 (Georgia World Congress Center)

Prospective Observational Study of 110 Multiple Myeloma (MM) Patients On Monthly Versus 3 Monthly Infusion of Zoledronic Acid

Ashraf Z. Badros, MD1, Sunita Philip2*, Patricia Lesho3*, Dianna Weikel4*, Olga Goloubeva3*, Mariola Sadowska5*, Rena Lapidus, PhD5*, Lisa Hester5*, Todd Milliron7* and Timothy Meiller8*

Number: 4245
Program: Oral and Poster Abstracts
Session: 901. Health Services and Outcomes Research: Poster III
Time and Location:
Monday, December 10, 2012: 6:00 PM-8:00 PM
Hall B1-B2 (Georgia World Congress Center)

Association Between FDA Safety Warnings, CMS Coverage Restrictions and Adherence to Guidelines for ESA Use in Patients with Myelodysplastic Syndromes

Franklin Hendrick, B.S.1*, Amy J. Davidoff, M.S., Ph.D.1* , Amer M. Zeidan, MD2, Steven D. Gore, MD2 and Maria R. Baer, M.D.3

Number: 971
Program: Oral and Poster Abstracts
Session: 901. Health Services and Outcomes Research: Malignant Hematology
Time and Location:
Tuesday, December 11, 2012: 7:30 AM-9:00 AM
C211-C213 (Georgia World Congress Center)


This page was last updated on: December 12, 2012.


For More Information